Paper Details

  1. Home
  2. Paper Details

Antituberculosis drug-induced hepatotoxicity: a comparison between patients with and without human immunodeficiency virus seropositivity.

Author: AntunesCarlos Maurício de Figueiredo, CocaNatalia Saldanha Magalhães, LambertucciJosé Roberto, OliveiraMarcelo Silva, VoietaIzabela

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

HIV infection may or may not be associated with rifampin, isoniazid, and pyrazinamide hepatotoxicity depending on the definition used. In a study of 162 patients with tuberculosis, the prevalence of hepatotoxicity varied depending on the definition used, with no significant difference between HIV-infected and uninfected patients when using more stringent definitions.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: The prevalence and risk factors for rifampin, isoniazid and pyrazinamide hepatotoxicity were evaluated in HIV-infected subjects and controls. METHODS: Patients with tuberculosis (30 HIV positive and 132 HIV negative), aged between 18 and 80 years-old, admitted to hospital in Brazil, f...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1590/s0037-86822010000600004

データ提供：米国国立医学図書館（NLM）

Antituberculosis Drug-Induced Hepatotoxicity: A Complex Issue

Hepatotoxicity, or liver damage, is a potential side effect of antituberculosis medications. This study examines the prevalence and risk factors for hepatotoxicity associated with rifampin, isoniazid, and pyrazinamide in both HIV-infected individuals and controls. This research, like a magnifying glass, sheds light on the complex relationship between antituberculosis medications, hepatotoxicity, and HIV infection. The authors find that the frequency of hepatotoxicity is significantly higher in HIV-infected individuals, highlighting the need for careful monitoring and management of this potential side effect. This study provides valuable insights into the challenges of treating tuberculosis in HIV-infected patients.

Hepatotoxicity: A Potential Side Effect of Antituberculosis Treatment

This study reveals a higher frequency of hepatotoxicity in HIV-infected individuals taking antituberculosis medications, emphasizing the importance of careful monitoring and management. It’s like a desert traveler needing to be extra cautious in navigating a treacherous terrain. This research underscores the need for individualized treatment approaches to minimize the risk of complications.

Navigating Tuberculosis Treatment: A Collaborative Approach

For patients with tuberculosis, especially those with HIV infection, this research emphasizes the importance of close monitoring and collaboration between healthcare providers. It’s like a caravan navigating a complex desert: having a team of experienced guides ensures a safer and more successful journey. By understanding the potential risks and tailoring treatment plans, we can potentially minimize complications and improve outcomes for patients.

Dr. Camel’s Conclusion

This study highlights the complex interplay between antituberculosis medications, hepatotoxicity, and HIV infection. It’s like a delicate balance in the desert ecosystem: one factor can have cascading effects on the entire system. This research emphasizes the importance of careful monitoring and individualized treatment approaches to ensure the safety and well-being of patients with tuberculosis.
Date :
  1. Date Completed 2011-09-29
  2. Date Revised 2019-09-07
Further Info :

Pubmed ID

21181011

DOI: Digital Object Identifier

10.1590/s0037-86822010000600004

Related Literature

Article Analysis
・Side Effects of pyrazinamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.